💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Voglibose

CHEMBL476960 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
267.3 g/mol
LogP
-4.1
Phase
4

Voglibose is an alpha-glucosidase inhibitor that competitively blocks intestinal alpha-glucosidase enzymes (maltase, sucrase, glucoamylase) on the brush border of the small intestine, delaying the digestion of complex carbohydrates and disaccharides and reducing postprandial glucose absorption. It is used primarily in Asian countries for type 2 diabetes mellitus management to reduce postprandial hyperglycemia with minimal risk of hypoglycemia. Its selective action on intestinal alpha-glucosidases results in localized effects with limited systemic absorption.

น้ำหนักโมเลกุล

267.2800 g/mol

LogP

-4.10

TPSA

154.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O

                

                

                
                

                    
InChI

                    
InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C10H21NO7

                    

                    
                    

                        
HBD / HBA

                        
8 / 8

                    

                    
                    

                        
พันธะที่หมุนได้

                        
5

                    

                    
                    
                    

                        
อะตอมหนัก

                        
18

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
Voglibose is an alpha-glucosidase inhibitor that competitively blocks intestinal alpha-glucosidase enzymes (maltase, sucrase, glucoamylase) on the brush border of the small intestine, delaying the digestion of complex carbohydrates and disaccharides and reducing postprandial glucose absorption. It is used primarily in Asian countries for type 2 diabetes mellitus management to reduce postprandial hyperglycemia with minimal risk of hypoglycemia. Its selective action on intestinal alpha-glucosidases results in localized effects with limited systemic absorption.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Voglibose is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL476960.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 444020.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.